David Hanna - Sadot Executive GM
| SDOT Stock | 3.96 0.09 2.33% |
Executive
David Hanna is Executive GM of Sadot Group
| Age | 48 |
| Address | 1751 River Run, Fort Worth, TX, United States, 76107 |
| Phone | 832 604 9568 |
| Web | https://www.sadotgroupinc.com |
David Hanna Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Hanna against Sadot stock is an integral part of due diligence when investing in Sadot. David Hanna insider activity provides valuable insight into whether Sadot is net buyers or sellers over its current business cycle. Note, Sadot insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sadot'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Hanna over six months ago Disposition of 263432 shares by David Hanna of Atlanticus Holdings at 28.4 subject to Rule 16b-3 |
Sadot Management Efficiency
The company has return on total asset (ROA) of (0.0605) % which means that it has lost $0.0605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2016) %, meaning that it created substantial loss on money invested by shareholders. Sadot's management efficiency ratios could be used to measure how well Sadot manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.05 in 2024. Return On Capital Employed is likely to gain to -0.13 in 2024. Total Current Liabilities is likely to gain to about 109.8 M in 2024. Non Current Liabilities Total is likely to gain to about 51.7 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Murphy | Regeneron Pharmaceuticals | 65 | |
| Bonne MBA | Inhibrx | 47 | |
| Josep Garcia | Inhibrx | N/A | |
| Aaron Alt | Cardinal Health | 52 | |
| Maxim CFA | Mind Medicine | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| Bill Clark | National Vision Holdings | 49 | |
| George JD | Asbury Automotive Group | 56 | |
| Paul Myrick | National Vision Holdings | 59 | |
| John Adams | Cardinal Health | N/A | |
| Bob McKinzie | National Vision Holdings | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Mary Scherer | Cardinal Health | N/A | |
| David MBA | Inhibrx | N/A | |
| Joe VanDette | National Vision Holdings | 46 | |
| Matt Sims | Cardinal Health | N/A | |
| Melissa Lozner | Regeneron Pharmaceuticals | N/A | |
| Melissa Rasmussen | National Vision Holdings | 47 | |
| Heidi Henneman | National Vision Holdings | N/A | |
| Gerald Underwood | Regeneron Pharmaceuticals | N/A | |
| Christopher CPA | Regeneron Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0605 |
Sadot Group Leadership Team
Elected by the shareholders, the Sadot's board of directors comprises two types of representatives: Sadot inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sadot. The board's role is to monitor Sadot's management team and ensure that shareholders' interests are well served. Sadot's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sadot's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Roper, CEO Secretary | ||
| Jaime Rueda, VP Ingredients | ||
| Aimee Infante, Chief Officer | ||
| Rodney Silva, LLC Brands | ||
| David Hanna, Executive GM | ||
| Kenneth Miller, Chief Officer | ||
| Jennifer Black, Chief Officer | ||
| Kevin Mohan, Chief Chairman | ||
| Benjamin Petel, Secretary Director |
Sadot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sadot a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0605 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 21.87 M | ||||
| Shares Outstanding | 5.74 M | ||||
| Shares Owned By Insiders | 24.66 % | ||||
| Shares Owned By Institutions | 10.90 % | ||||
| Number Of Shares Shorted | 42.03 K | ||||
| Price To Book | 0.72 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sadot Stock Analysis
When running Sadot's price analysis, check to measure Sadot's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sadot is operating at the current time. Most of Sadot's value examination focuses on studying past and present price action to predict the probability of Sadot's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sadot's price. Additionally, you may evaluate how the addition of Sadot to your portfolios can decrease your overall portfolio volatility.